Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Amicus Therapeutics (FOLD) over the last 15 years, with Q3 2025 value amounting to $17.0 million.

  • Amicus Therapeutics' Tax Provisions rose 2555.87% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 4759.48%. This contributed to the annual value of $27.4 million for FY2024, which is 174423.47% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Tax Provisions is $17.0 million, which was up 2555.87% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Tax Provisions ranged from a high of $17.0 million in Q3 2025 and a low of -$14.2 million during Q4 2022
  • Its 5-year average for Tax Provisions is $3.1 million, with a median of $3.0 million in 2021.
  • Examining YoY changes over the last 5 years, Amicus Therapeutics' Tax Provisions showed a top increase of 231043.96% in 2022 and a maximum decrease of 57681.99% in 2022.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Tax Provisions stood at $3.0 million in 2021, then tumbled by 576.82% to -$14.2 million in 2022, then soared by 115.36% to $2.2 million in 2023, then plummeted by 411.73% to -$6.8 million in 2024, then skyrocketed by 349.35% to $17.0 million in 2025.
  • Its Tax Provisions stands at $17.0 million for Q3 2025, versus $5.2 million for Q2 2025 and $3.6 million for Q1 2025.